Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
SL VAXiGEN
NGM Biopharmaceuticals, Inc
Nanfang Hospital, Southern Medical University
Brigham and Women's Hospital
Consorzio Oncotech
Kineta Inc.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
University Hospital Freiburg
Cambridge University Hospitals NHS Foundation Trust
University College, London
The Christie NHS Foundation Trust
Portland VA Medical Center
Erasmus Medical Center
Tianjin Medical University Second Hospital
IRCCS San Raffaele
Institute of Cancer Research, United Kingdom
MultiVir, Inc.